On Demand: Better Together: How Pharmacy and Cardiology Partnerships Elevate the Transthyretin Amyloidosis Care Delivery Journey-Webinar Slides

Webinar Slides

Pdf Summary

This webinar, “Better Together: How Pharmacy and Cardiology Partnerships Elevate the Transthyretin Amyloidosis (ATTR) Care Delivery Journey,” features a panel of pharmacy and cardiovascular leaders discussing how cross-functional collaboration can improve identification, diagnosis, and treatment delivery for ATTR, a rare, progressive disease caused by misfolded transthyretin protein deposits. ATTR commonly manifests as cardiomyopathy (ATTR-CM) and/or hereditary polyneuropathy (hATTR-PN), with a median U.S. onset age of 68. ATTR-CM is associated with heart failure symptoms, arrhythmias, frequent and costly hospitalizations, and poor survival when untreated.<br /><br />The presentation highlights major gaps in the U.S. care continuum: ATTR is underdiagnosed and undertreated. Estimates indicate only ~40% to 62% of patients are diagnosed, and only ~25% to 44% of diagnosed patients receive treatment. These gaps increase health system burden, as untreated ATTR-CM patients have higher hospitalization rates than other heart failure patients and hospital stays may be longer and more expensive.<br /><br />Two Alnylam/Becker’s Healthcare surveys (2025) of health system executives, finance leaders, cardiovascular service line (CVSL) leaders, and pharmacy leaders identify operational and workflow barriers. Identification and outreach to at-risk patients is fragmented, relying on varied methods such as cardiology screening protocols, genetic/family history, ad hoc EHR searches, pharmacy medication reconciliation, and referrals from other specialties. Many systems report limited ability to accelerate diagnosis due to resource constraints, insufficient provider awareness, lack of standardized protocols, coordination challenges across specialties, and limited EHR decision support. Only about one-third rate cross-department coordination as very effective; multidisciplinary case conferences and shared EHR dashboards are viewed as the most helpful coordination tools.<br /><br />The panel emphasizes optimizing operational pathways for provider-administered medications. Centralized pharmacy services commonly support benefit determination, prior authorization, and coordination across multiple sites of care (infusion centers, ambulatory clinics, physician offices, alternate sites, and in-home administration). Survey respondents cite “buy-and-bill” advantages including drug supply chain integrity, improved patient safety/monitoring, complete EHR capture, better continuity of care, patient satisfaction, adherence support, and revenue capture.

Keywords

Transthyretin amyloidosis (ATTR)

ATTR cardiomyopathy (ATTR-CM)

Hereditary ATTR polyneuropathy (hATTR-PN)

Pharmacy and cardiology collaboration

Underdiagnosis and undertreatment gaps

Care continuum and care delivery pathway

EHR screening and decision support

Multidisciplinary case conferences

Centralized pharmacy services and prior authorization

Buy-and-bill provider-administered medications